Compare DexCom, Inc. (DXCM) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Strategy Inc. — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Strategy Inc. trades at $154.8 (market cap $60.40B). The key difference: Strategy Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Strategy Inc. for 112 Days on average.
| DXCM | MSTR | |
|---|---|---|
Market Cap | $31.86B | $60.40B |
Volume | 3,607,070 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $92.34 | $320.29 |
52-Week Low | $54.84 | $82.31 |
Typical Hold Time | 62 Days | 112 Days |
Enterprise Value | $31.32B | $79.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
MSTR stock trades at $153.37, down 6.79% today, reflecting volatility despite a bullish technical signal. The company reported a net loss of $3.85B in 2025 with a negative net income margin of -6,102.96%, though revenue grew slightly to $477.23M. Analyst consensus remains optimistic with a $252 price target, but earnings misses in recent quarters highlight operational challenges.
The outlook hinges on improving profitability and Bitcoin market stability, offering upside if earnings rebound. Key risks include persistent losses, high debt, and sensitivity to macroeconomic factors. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
